NewsBenzinga오토루스 테라퓨틱스, 진행 중인 CARLYSLE 1상 시험의 장기 추적 데이터 발표···기초 질환 활성도가 심각함에도 불구하고 대부분의 환자에서 SLEDAI-2K 점수의 임상적으로 유의미한 개선 및 DORIS 달성 확인 오토루스 테라퓨틱스, 진행 중인 CARLYSLE 1상 시험의 장기 추적 데이터 발표···기초 질환 활성도가 심각함에도 불구하고 대부분의 환자에서 SLEDAI-2K 점수의 임상적으로 유의미한 개선 및 DORIS 달성 확인 Benzinga 2026.11.10 21:18 (GMT+0) Open on Benzinga Other news 'China Taps US AI Models To Train Homegrown Rivals As Chip Curbs Bite' - Reuters Exclusive 'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century' A-Share Close: ChiNext Index Down Over 1% After Intraday Reversal, More Than 4,100 Stocks Fall Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen Aytu BioPharma Stock Climbs 44% After-Hours: Here's Why Reported Earlier, MediaCo Holding Q3 EPS $(0.11) Up From $(0.22) YoY, Sales $28.600M Down From $35.398M YoY
'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century'
Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen
Reported Earlier, MediaCo Holding Q3 EPS $(0.11) Up From $(0.22) YoY, Sales $28.600M Down From $35.398M YoY